<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584674</url>
  </required_header>
  <id_info>
    <org_study_id>CL-K1005-P001</org_study_id>
    <nct_id>NCT01584674</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating the Safety and Efficacy of the KLOX Biophotonic System in Moderate to Severe Acne</brief_title>
  <official_title>A Prospective Clinical Trial Evaluating the Efficacy of the KLOX Biophotonic System (KLOX KLGA0105-01 and KLOX THERA LAMP) On Moderate to Severe Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KLOX Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KLOX Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the KLOX Biophotonic
      System in patients with moderate to severe facial acne vulgaris using a split-face design
      (treated hemiface vs untreated hemiface).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving a total reduction of at least 2 grades in the Investigator's Global Assessment (IGA) scale</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in inflammatory lesions</measure>
    <time_frame>6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a reduction of at least 1 grade in the Investigator's Global Assessment (IGA) scale</measure>
    <time_frame>6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a reduction to grade 1 or 0 in the Investigator's Global Assessment (IGA) scale</measure>
    <time_frame>6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction questionnaire</measure>
    <time_frame>6 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment using a visual analogue scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluations (treatment-emergent and treatment related adverse events)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>KLOX Biophotonic System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (untreated hemiface)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment will be administered on the control hemiface</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KLOX Biophotonic System</intervention_name>
    <description>KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period</description>
    <arm_group_label>KLOX Biophotonic System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female 16 - 30 years of age.

          2. Fitzpatrick skin type I through IV.

          3. Known medical history of active acne vulgaris for at least 6 months.

          4. Moderate-to-severe facial acne, as defined by:

             Moderate is defined as a patient with an IGA of 3 with 20 to 40 inflammatory lesions
             (papules and pustules) and no more than 1 nodule. Severe is defined as a patient with
             an IGA of 4 with a greater than 40 inflammatory lesions with the presence of no more
             than 2 nodules and/or inflammatory scaring type lesion. Also note that all patients
             should have a similar disease stage on both sides of their face.

          5. The patient must have a clinical examination prior to treatment.

          6. The patient must have signed the consent form.

          7. The patient must be willing to return for follow-up visits.

          8. Females of child bearing potential must have a negative pregnancy test result at
             baseline and both male and female patients must be willing to adhere to a birth
             control method.

        Exclusion Criteria:

          1. Active skin infection on the face. Patient must not have active, localized or systemic
             infection.

          2. Facial aesthetic procedure, including laser therapy and injectables within the last 6
             months.

          3. Enrollment in another acne study or other dermatological study using light therapy
             including tanning beds within 120 days of enrollment. Patients must not take part or
             intend to take part in another study liable to interfere with this study whatever the
             region of the body considered for 30 days prior to the study start and 30 days
             following completion of the study.

          4. History of head and/or neck irradiation.

          5. Use of a hormonal contraception is prohibited unless the birth control has been stable
             for the past 3 months. Note that patient that are presently taking or have taken in
             past 30 days Cyproterone Acetate + Ethinyl Estradiol (Diane-35) are not eligible for
             this study.

          6. Any facial dermatological conditions that could hinder or interfere with clinical
             assessments.

          7. Immunosuppression and/or cortisone therapy in the past 4 months.

          8. Bleeding diathesis.

          9. Medications or supplements affecting coagulation.

         10. Isotretinoin within the last 24 weeks.

         11. Pregnant, breast-feeding or pregnancy planned during the trial.

         12. History of facial nerve palsy or marked facial asymmetry.

         13. History of neuromuscular disorder.

         14. Prior facial surgery that alters subcutaneous tissues (e.g., rhytidectomy).

         15. Use of non-acne topical medication that could interfere with study treatment.

         16. Physical or psychiatric condition the investigator deems would preclude participation
             in the study. (e.g. Polycystic Ovary disease)

         17. Unwillingness to refrain from excess sun exposure or tanning beds during the healing
             process -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Attikon University General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andreas Sygros Hospital</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papageorgiou Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

